TMDX fundamentals
Key facts
Market capitalization4.30 BUSD
Basic EPS (TTM)1.46USD
Founded1998
CEOWaleed H. Hassanein
Websitetransmedics.com
About
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
Valuation
Fundamental metrics to determine fair value of the stock
4.30 B
Price to earning ratio (P/E)
93.85xPrice to sales ratio (P/S)
10.44xMarket Cap
Net income
Revenue
Price to earning ratio (P/E)
93.85xPrice to sales ratio (P/S)
10.44xGrowth and Profitability
Company’s recent performance and margins
3.5%
7.5%
11.5%
15.5%
19.5%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
40.00 M
80.00 M
120.00 M
160.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
No dividends
TMDX has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company